Craig W. Freyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Craig W. Freyer has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Meir Wetzler
Roswell Park Cancer Institute, Department of Medicine, Leukemia Section, Elm and Carlton Streets, Buffalo, NY 14263, USA
3 shared publicationsEunice S. Wang
Department of Medicine, Leukemia Service Roswell Park Cancer Institute Buffalo New York
2 shared publicationsBritny Rogala
Roswell Park Cancer Institute, Department of Pharmacy, Elm and Carlton Streets, Buffalo, NY 14263, USA
1 shared publicationElizabeth A Griffiths
Roswell Park Cancer Institute, Department of Medicine, Leukemia Section, Elm and Carlton Streets, Buffalo, NY 14263, USA
1 shared publicationElizabeth A. Griffiths
Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States
1 shared publication- Elizabeth A. Griffiths
Roswell Park Comprehensive Cancer Center, Buffalo, USA
1 shared publication
Latest Publications
- 1 June 2015
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 15, S187
Decitabine and sorafenib therapy in FLT3-ITD mutant acute myeloid leukemia- A case series
- 1 June 2015
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 15, S187
Decitabine and sorafenib therapy in FLT3-ITD mutant acute myeloid leukemia- A case series
- 2 February 2015
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 15 (6) , 895-908
Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies
Introduction: The approval of blinatumomab signals the long awaited arrival of immunotherapy for acute lymphoblastic leukemia (ALL). Previous options for relapsed or refractory disease were restric...
- 2 February 2015
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 15 (6) , 895-908
Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies
Introduction: The approval of blinatumomab signals the long awaited arrival of immunotherapy for acute lymphoblastic leukemia (ALL). Previous options for relapsed or refractory disease were restric...
- 25 October 2014
- Published by Wiley in American Journal of Hematology
- Vol. 90 (1) , 62-72
Revisiting the role of cladribine in acute myeloid leukemia: An improvement on past accomplishments or more old news?
Originally studied in lymphoid diseases, cladribine (CdA) is an adenosine deaminase resistant analog of adenosine that was later discovered to induce myeloid cell apoptosis. The activity of CdA in myeloid malignancies was first reported in relapsed/refractory (RR) pediatric acute myeloid leukemia (AML) with complete response (CR) rates of up to 47%. Consequently, several studies have confirmed the efficacy of single agent CdA or CdA combination regimens in AML. Established CR rates for combination regimens in RR adults are approximately 50%, while CR rates for newly diagnosed (ND) adults are approximately 70% and show similar toxicity profiles to previously used regimens. Despite these promising data, many centers have yet to adopt CdA combination regimens for these difficult to treat populations. We review the pharmacology, pharmacokinetics, clinical data, and safety of CdA monotherapy and combination regimens for the management of pediatric and adult ND and RR‐AML. Am. J. Hematol. 90:62–72, 2015.
- 25 October 2014
- Published by Wiley in American Journal of Hematology
- Vol. 90 (1) , 62-72
Revisiting the role of cladribine in acute myeloid leukemia: An improvement on past accomplishments or more old news?
Originally studied in lymphoid diseases, cladribine (CdA) is an adenosine deaminase resistant analog of adenosine that was later discovered to induce myeloid cell apoptosis. The activity of CdA in myeloid malignancies was first reported in relapsed/refractory (RR) pediatric acute myeloid leukemia (AML) with complete response (CR) rates of up to 47%. Consequently, several studies have confirmed the efficacy of single agent CdA or CdA combination regimens in AML. Established CR rates for combination regimens in RR adults are approximately 50%, while CR rates for newly diagnosed (ND) adults are approximately 70% and show similar toxicity profiles to previously used regimens. Despite these promising data, many centers have yet to adopt CdA combination regimens for these difficult to treat populations. We review the pharmacology, pharmacokinetics, clinical data, and safety of CdA monotherapy and combination regimens for the management of pediatric and adult ND and RR‐AML. Am. J. Hematol. 90:62–72, 2015.
- 28 February 2014
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 30 (2) , 43-47
Drug-Induced Aseptic Meningitis Associated With Intrathecal Trastuzumab
Objective: To report a case of drug-induced aseptic meningitis (DIAM) in a patient receiving intrathecal trastuzumab (ITT) for leptomeningeal carcinomatosis (LC) secondary to HER-2/neu positive breast cancer. Case Summary: A 43-year-old female with stage IV breast cancer presented with headache, parasthesias, and aphasia. Brain imaging suggested leptomeningeal enhancement. Adenocarcinoma cells were found on cerebrospinal fluid analysis, and infectious etiologies were excluded. The patient received 30 mg of ITT via Ommaya reservoir and suffered sudden neurologic deterioration within 2 hours. Given the sudden onset of clinical deterioration after ITT administration, it was determined that the patient had suffered from DIAM. The patient suffered progressive neurologic decline and was unable to care for herself any further. Discussion: Treatment for LC remains challenging due to limited clinical experience and the challenging location of the disease. ITT has been used in multiple reports without adverse events. A temporal relationship existed between ITT administration and significant neurologic deterioration, possibly related to DIAM. Our patient was not exposed to any more common causative agents of DIAM. Reasons for her lack of recovery are likely multifactorial. Symptoms of DIAM may have in part been exacerbated by progressive LC; however, prior to ITT, symptoms had shown slow but persistent progression rather than significant, acute changes in severity. Retrial of the offending agent was not attempted due to patient risk; thus, a cause-and-effect relationship cannot be established. This event is a “possible” drug-induced adverse event scoring 2 on the Naranjo algorithm. Conclusions: Use of ITT for LC has been frequently reported in recent literature with substantial efficacy and lack of adverse events. This is the first published report of any significant adverse event associated with ITT. Clinicians need to be aware of the possibility of DIAM with ITT and explore options to prevent or manage this severe complication.
- 28 February 2014
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 30 (2) , 43-47
Drug-Induced Aseptic Meningitis Associated With Intrathecal Trastuzumab
Objective: To report a case of drug-induced aseptic meningitis (DIAM) in a patient receiving intrathecal trastuzumab (ITT) for leptomeningeal carcinomatosis (LC) secondary to HER-2/neu positive breast cancer. Case Summary: A 43-year-old female with stage IV breast cancer presented with headache, parasthesias, and aphasia. Brain imaging suggested leptomeningeal enhancement. Adenocarcinoma cells were found on cerebrospinal fluid analysis, and infectious etiologies were excluded. The patient received 30 mg of ITT via Ommaya reservoir and suffered sudden neurologic deterioration within 2 hours. Given the sudden onset of clinical deterioration after ITT administration, it was determined that the patient had suffered from DIAM. The patient suffered progressive neurologic decline and was unable to care for herself any further. Discussion: Treatment for LC remains challenging due to limited clinical experience and the challenging location of the disease. ITT has been used in multiple reports without adverse events. A temporal relationship existed between ITT administration and significant neurologic deterioration, possibly related to DIAM. Our patient was not exposed to any more common causative agents of DIAM. Reasons for her lack of recovery are likely multifactorial. Symptoms of DIAM may have in part been exacerbated by progressive LC; however, prior to ITT, symptoms had shown slow but persistent progression rather than significant, acute changes in severity. Retrial of the offending agent was not attempted due to patient risk; thus, a cause-and-effect relationship cannot be established. This event is a “possible” drug-induced adverse event scoring 2 on the Naranjo algorithm. Conclusions: Use of ITT for LC has been frequently reported in recent literature with substantial efficacy and lack of adverse events. This is the first published report of any significant adverse event associated with ITT. Clinicians need to be aware of the possibility of DIAM with ITT and explore options to prevent or manage this severe complication.
- Open Access
- 1 January 2014
- Published by Elsevier in Leukemia Research Reports
- Vol. 3 (2) , 62-66
High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure
- 1 January 2014
- Published by Elsevier in Leukemia Research Reports
- Vol. 3 (2) , 62-66
Open AccessHigh pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure